The Ohara Pharmaceutical-backed small-molecule therapy developer has secured $11.8m from new and returning investors.

Prism BioLab, a Japan-based peptide mimetics technology developer backed by pharmaceutical firm Ohara Pharmaceutical, has raised ¥1.3bn ($11.8m) in a series C round led by venture capital firm DCI Partners.

The round included Development Bank of Japan’s DBJ Capital unit as well as Newton BioCapital Partners, Healthcare Innovation and Gemseki.

Founded in 2006 as Prism Pharma, Prism BioLab is developing small-molecule drug discovery technology targeting hitherto undruggable proteins. It has two clinical-stage programmes, focusing on cancer and fibrosis.

The company…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn